Iovance Biotherapeutics, Inc. (IOVA) fundamentals score
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Its mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 6.0 out of 10, Mixed fundamentals
- Growth: 7.7/10
- Profitability: 3.7/10
- Financial health: 8.5/10
- Earnings quality: 6.4/10
- Valuation: 3.2/10
Scores are calculated from Iovance Biotherapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10